You can't always believe what you read in the press. Rarely do they get the full story accurately. In any case, that's all history which can't be changed. I think whats really important now is that all three Nilotinib trials (GU. MJFF et al, and Inhibikase) are scheduled to begin in 2017. Given the total sample size will be quite large when looking across all three studies, we should get a good feel for how effective the drug is (or isn't) in improving symptoms and slowing progression.